Search
forResearch 10 of 1000+
- Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Medications affecting the insulin-like growth factor 1/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study
- Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase
- Sun behaviors and quality of life after first cutaneous melanoma diagnosis
- Sun protection policies and behaviors among U.S. child care centers
- Sunscreen: Cosmetic or medical therapy?
- En pacientes jóvenes, el uso de finasteride podría asociarse con mayor riesgo de ansiedad, depresión y eventos adversos relacionados con el suicidio
- Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →